BioCentury
ARTICLE | Clinical News

Starlix nateglinide (A-4166): Began Phase III trial

September 17, 2001 7:00 AM UTC

Novartis AG (NVS; SWX:NOVN), Basel, Switzerland Product: Starlix nateglinide ( A-4166) Business: Metabolic Therapeutic category: Metabolism Target: Pancreatic beta cells Description: Derivative of d-...